IN2013CN09704A - - Google Patents
Info
- Publication number
- IN2013CN09704A IN2013CN09704A IN9704CHN2013A IN2013CN09704A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A IN 9704CHN2013 A IN9704CHN2013 A IN 9704CHN2013A IN 2013CN09704 A IN2013CN09704 A IN 2013CN09704A
- Authority
- IN
- India
- Prior art keywords
- mirabegron
- preparation
- form crystal
- amorphous
- aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
Abstract
Aspects of the present invention relate to amorphous form of mirabegron amorphous solid dispersion of mirabegron process for its preparation processes for preparation of a form crystal and ß form crystal of mirabegron and pharmaceutical composition thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN9704CHN2013 IN2013CN09704A (en) | 2011-05-18 | 2012-05-17 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1678CH2011 | 2011-05-18 | ||
US201161502911P | 2011-06-30 | 2011-06-30 | |
PCT/IN2012/000356 WO2012156998A2 (en) | 2011-05-18 | 2012-05-17 | Amorphous mirabegron and processes for crystal forms of mirabegron |
IN9704CHN2013 IN2013CN09704A (en) | 2011-05-18 | 2012-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013CN09704A true IN2013CN09704A (en) | 2015-07-03 |
Family
ID=47177412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN9704CHN2013 IN2013CN09704A (en) | 2011-05-18 | 2012-05-17 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9283210B2 (en) |
EP (1) | EP2709993A4 (en) |
IN (1) | IN2013CN09704A (en) |
WO (1) | WO2012156998A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9655885B2 (en) * | 2011-05-18 | 2017-05-23 | Dr. Reddy's Laboratories Ltd. | Amorphous mirabegron and processes for crystal forms of mirabegron |
CN103193730A (en) * | 2013-04-17 | 2013-07-10 | 苏州永健生物医药有限公司 | Synthesis method of mirabegron |
WO2015040573A1 (en) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder |
WO2015040605A1 (en) | 2013-09-23 | 2015-03-26 | Ranbaxy Laboratories Limited | Crystalline form of mirabegron |
WO2015044965A1 (en) | 2013-09-30 | 2015-04-02 | Megafine Pharma (P) Ltd. | A process for preparation of mirabegron and alpha crystalline form thereof |
ITMI20131653A1 (en) | 2013-10-07 | 2015-04-08 | Dipharma Francis Srl | CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST |
CA2962664A1 (en) * | 2014-10-01 | 2016-04-07 | Apotex Inc. | Solid forms of mirabegron |
EP3253741A1 (en) | 2015-02-02 | 2017-12-13 | Lupin Limited | Process for preparation of polymorphic form of mirabegron |
WO2016181283A1 (en) * | 2015-05-11 | 2016-11-17 | Aurobindo Pharma Ltd | A PROCESS FOR THE PREPARATION OF MIRABEGRON α-FORM CRYSTALS |
JP6618736B2 (en) * | 2015-09-01 | 2019-12-11 | 沢井製薬株式会社 | Mirabegron-containing tablet, method for producing mirabegron-containing preparation, and method for producing mirabegron-containing granulated product |
FR3043555B1 (en) * | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | MIRABEGRON FOR THE TREATMENT OF RETINAL DISEASES |
EP3184516A1 (en) | 2015-12-23 | 2017-06-28 | Enantia, S.L. | Crystalline inclusion complexes of mirabegron with beta-cyclodextrin |
KR101937713B1 (en) * | 2017-07-14 | 2019-01-14 | 주식회사 대웅제약 | Pharmaceutical formulation and preparation method for the same |
KR101928987B1 (en) * | 2018-08-28 | 2018-12-13 | (주) 성운파마코피아 | A New and Highly Pure Crystalline monohydrate of mirabegron, Method for Preparing or Use Thereof |
CN110590699B (en) * | 2019-09-29 | 2022-11-15 | 广东先强药业有限公司 | Refining method of mirabegron |
CN112745276B (en) * | 2019-10-31 | 2023-10-03 | 四川国为制药有限公司 | Crystallization method of milbegron |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
CN114539182A (en) * | 2020-11-24 | 2022-05-27 | 威智医药有限公司 | Crystal transformation solvent and application thereof, and preparation method of mirabegron alpha crystal form |
KR102333167B1 (en) | 2021-05-26 | 2021-12-01 | 유니셀랩 주식회사 | An efficient and mass-producible Mirabegron amorphous manufacturing method |
CN113773274A (en) * | 2021-08-09 | 2021-12-10 | 石药集团中奇制药技术(石家庄)有限公司 | Recrystallization method of mirabegron alpha crystal form raw material |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID23989A (en) | 1997-10-17 | 2000-06-14 | Yamanouchi Pharma Co Ltd | THE AMIDA DOWNS OR THE SALT |
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
CA2503570C (en) | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
-
2012
- 2012-05-17 WO PCT/IN2012/000356 patent/WO2012156998A2/en active Application Filing
- 2012-05-17 EP EP12785575.7A patent/EP2709993A4/en not_active Withdrawn
- 2012-05-17 US US14/117,569 patent/US9283210B2/en not_active Expired - Fee Related
- 2012-05-17 IN IN9704CHN2013 patent/IN2013CN09704A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2709993A2 (en) | 2014-03-26 |
EP2709993A4 (en) | 2015-02-25 |
US9283210B2 (en) | 2016-03-15 |
US20140206729A1 (en) | 2014-07-24 |
WO2012156998A3 (en) | 2013-01-17 |
WO2012156998A2 (en) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2013CN09704A (en) | ||
HK1196849A1 (en) | Recombinant microorganism for the production of useful metabolites | |
PT2744768T (en) | Process for the production of ternesite clinker | |
IN2015KN00262A (en) | ||
MX2015005891A (en) | Polymorphic forms of suvoroxant. | |
EP2669411A4 (en) | Silicon melt contacting member and process for production thereof, and process for production of crystalline silicon | |
PL2785701T3 (en) | Crystalline form of carbazitaxel and process for preparation thereof | |
PL2806745T3 (en) | Process for producing a composition containing active follistatin | |
EA029539B8 (en) | Pharmaceutical composition of sitagliptin | |
MX2014010433A (en) | Novel crystalline form of sitagliptin sulfate. | |
IL229647A0 (en) | Novel process for the preparation of prostaglandin amides | |
HK1198584A1 (en) | Process for the preparation of travoprost | |
WO2014068586A3 (en) | Solid oral compositions of tolvaptan | |
EP2732028A4 (en) | Compositons and methods for the production of isoprene | |
WO2012131707A3 (en) | Crystalline form of bortezomib, preparation method and pharmaceutical composition there f | |
EP2671847A4 (en) | Process for manufacture of phosphor-dispersed glass, and phosphor-dispersed glass | |
EP2589662A4 (en) | Process for production of useful substance | |
MX2012010443A (en) | Process for the preparation of 5-substituted 1-alkyltetrazoles. | |
IN2014DN09451A (en) | ||
WO2014102759A3 (en) | Process for the preparation of dasatinib and its intermediates | |
MX2014009015A (en) | Stable amorphous raltegravir potassium premix and process for the preparation thereof. | |
HUP1100177A2 (en) | Recycled composition and process for preparation of it and production of regenarated, vulcanised gum | |
IN2013CH05282A (en) | ||
EP2694621B8 (en) | Methods for the production of fuel | |
PT2702045T (en) | Novel process for the preparation of etravirine |